Crage Medical Co., Limited

Carsgen Therapeutics Co., Ltd.

Carsgen Therapeutics Limited

Cafa Therapeutics Limited

Shanghai Yile Biotechnology Co., Ltd.

Shanghai Cancer Institute

Shanghai Yile Biotechnology Limited

Shanghai Yijie Biotechnology Co., Ltd

Huamao Wang

Zonghai Li

Hua Jiang

Bo Song

Xiumei Cai

Peng Wang

Huiping Gao

Bizhi Shi

Ruping Dai

Jianren Gu

Shengli Yang

Min Zhou

Hongxia Zhao

Hongyang Wang

Zhimin Shi

Juan Kong

Xinfu Zhou

Yuanmei Chen

Kesang Li

Yinyu Zhu

Hong Luo

Linlin Yang

Changqi Li

Disclosed in the present invention is a genetically engineered cell, expressing an exogenous receptor that specifically binds to a target antigen and exogenous CCL21, and capable of further expressing an IL-7R binding protein or exogenous IL-7 that promotes cell proliferation. Also disclosed are an expression construct comprising an exogenous CCL21 expression cassette, and a vector containing same, a virus, and a pharmaceutical composition comprising said cell. Also disclosed is an application for the cell, the expression construct, the vector, and the virus in the preparation of drugs for inhibiting tumours or inhibiting pathogens.

Genetically engineered cell and application thereof

Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.

Method and composition for treating tumors

The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.

Antibody against glypican-3 and application thereof

Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof

Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

Compositions and methods of cellular immunotherapy

Provided is an antibody that specifically recognizes IL-13RA2, which can be used in the manufacture of a targeting anti-tumor medicament as well as a medicament for diagnosing a tumor.

Antibody targeting IL-13RA2 and use thereof

Provided in the present invention are a specific antibody of BCMA and a BCMA-targeting immune effector cell, and also provided are a chimeric antigen receptor-modified T cell prepared using the antibody and the use thereof.

BCMA-targeting antibody and use thereof

An antibody for being specifically bound to a pro brain-derived neurotrophic factor (pro-BDNF) and a bound epitope. The antibody and the protein are used for treating autoimmune diseases. By inhibiting the activity induced by the pro-BDNF, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephriti, chronic obstructive pulmonary diseases, asthma or cystic fibrosis, multiple sclerosis and other autoimmune diseases are treated.

Polypeptide and antibody bound to polypeptide

Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.

GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof

Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours.

Antibody for anti-claudin 18A2 and use thereof

The present invention provides a tumor-specific anti-EGFR antibody and application thereof. The antibody can be used for preparing targeted antitumor drugs and tumor diagnosis drugs.

Tumor-specific anti-EGFR antibody and application thereof

The present invention provides fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin.

Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin

A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.

Chimeric antigen receptors targeting GPC3 and uses thereof

Disclosed herein is use of a binding molecule which specifically binds to a precursor of brain-derived neurotrophic factor (proBDNF). The binding molecule for proBDNF, especially a monoclonal antibody against proBDNF, can be used to prevent, mitigate or treat autoimmune diseases.

Growing community of inventors

Shanghai, China

Huamao Wang